Report Date: Wednesday, August 5, 2026, before market open | Call at 8:30 a.m. ET
Cencora heads into this print in an unusual position: the stock is trading essentially back where it was before its last earnings-day disaster. Shares cratered roughly 17-18% on May 6 after the company slashed its FY2026 revenue growth outlook, but they have since rallied hard — from a post-earnings low near $253 to roughly $306-$319 through June and July. Shares of Cencora tumbled 17.4% on May 6 after the company cut its fiscal-year revenue growth forecast to 4% - 6% following weaker-than-expected Q2 2026 results. That means expectations have reset meaningfully higher again, raising the bar for tomorrow's report.
Sentiment on the Street remains constructive but has become more dispersed post-guidance-cut: eleven analysts rate the stock Buy and three Hold, with an average "Moderate Buy" rating and an average price target of $367.75, though price targets have moved in both directions — Baird cut its target from $420 to $339 while keeping Outperform, and Citigroup cut from $405 to $355 while maintaining Buy, whereas BofA's Allen Lutz raised his target to $285 from $280 while keeping a Neutral rating. Notably, a plaintiffs' law firm has also opened an inquiry into the May sell-off: Cencora has drawn a newly announced investor rights investigation from law firm Pomerantz, which said it is reviewing potential claims on behalf of shareholders — a headline risk worth watching but not (yet) a fundamental one.
Cencora's fiscal Q2 (ended March 31, 2026) told a "beat on EPS growth, miss on revenue and guidance cut" story:
Since then, Cencora has twice sweetened the buyback story: on May 20, 2026, the Board authorized a new $2.0 billion share repurchase program, and the company nudged FY2026 adjusted EPS guidance up to $17.70-$17.90 (from $17.65-$17.90) as a result of recent opportunistic share repurchases completed in May, in line with its plan to buy back $1.0 billion of stock by year-end 2026. This is financial-engineering-driven upside (lower share count), not an operational re-acceleration — worth distinguishing from organic strength.
This will be the first earnings call for new CFO Eva Boratto, who joined effective June 29, 2026, succeeding retiring CFO Jim Cleary (who signed off on the May call and will remain in an advisory capacity through year-end). Boratto is an experienced public company executive with financial and operational experience across healthcare and consumer sectors, most recently as CFO of Bath & Body Works. Investors should listen for any shift in tone, disclosure detail, or capital-allocation framing under new financial leadership, though management reaffirmed guidance at the time of her appointment.
Estimates cluster tightly:
| Metric | Consensus | Y/Y |
|---|---|---|
| Adjusted EPS | ~$4.35-$4.37 | +~9% |
| Revenue | ~$84.3-$84.9 billion | +~5% |
| U.S. Healthcare Solutions revenue | ~$75.0 billion | +~2.9% |
| International Healthcare Solutions revenue | ~$7.8 billion | ~flat |
Analysts forecast Cencora to report adjusted EPS of $4.37, up 9.3% from $4.00 in the year-ago quarter, and the Zacks Consensus Estimate pegs revenue at $84.89 billion (up 5.2% y/y) and EPS at $4.37 (up 9.3% y/y). Estimate revisions have trended slightly positive: over the last 30 days there has been an upward revision of 1.3% in the consensus EPS estimate, and Cencora's Most Accurate Estimate sits above the Zacks Consensus, giving it an Earnings ESP of +1.49% and a Zacks Rank of #2 — a combination that historically favors a beat. That said, COR's beat record is imperfect: the company delivered a negative earnings surprise of 1.04% last quarter, beating estimates in three of the trailing four quarters and missing once, for an average surprise of 1.59%.
1. Has the revenue deceleration stabilized, or is there more downside? The three Q2 culprits — WAC/IRA price cuts, the mail-order customer's brand-to-biosimilar conversion pace, and decelerating GLP-1 growth — are all still live issues. Management flagged that GLP-1 growth is running slower than originally modeled and that a 5-point swing in GLP-1 growth is worth roughly $2 billion of annual revenue, so any commentary on GLP-1 volume trends (including the mix shift toward oral GLP-1s) will move the stock. Watch specifically whether the mail-order brand-conversion headwind is now "in the base" or still accelerating.
2. Is the promised second-half acceleration showing up? Management guided Q3 adjusted EPS growth to the "high single digits" and pointed to Q4 as the inflection point once the July 2025 oncology-customer loss is fully lapped and OneOncology accretion ramps further. Since the oncology-customer loss began hitting the base in July 2025, this Q3 (April-June 2026) print still carries that headwind — Q4 is when the comp turns easier. Confirmation that U.S. Healthcare Solutions operating income is tracking toward the 14-16% full-year growth target (unchanged from Q2 guidance) will be a key signal of guidance credibility.
3. MSO integration progress (OneOncology/RCA) and the EyeSouth bolt-on. Cross-platform synergies between OneOncology and Retina Consultants of America (RCA) were an early "growth priority" theme on the May call; look for updated color now that integration has had another quarter to mature, plus any update on the pending EyeSouth Partners retina acquisition (announced March 2026, not yet reflected in guidance).
4. Portfolio optimization: MWI/Covetrus and consulting divestiture cadence. The U.S. Consulting Services sale closed April 30, 2026, and the MWI Animal Health/Covetrus merger remains pending — both affect the "Other" segment's shape (already benefiting from MWI's asset-held-for-sale accounting, which suspended depreciation and lifted Other's operating income outlook to high-single-digit growth).
5. International — is the World Courier/global specialty logistics rebound continuing? International Healthcare Solutions posted a second consecutive quarter of specialty-logistics operating income growth in Q2, aided by new cell-and-gene-therapy and lab-logistics contracts. A third consecutive quarter of improvement would reinforce a real turnaround narrative there, separate from currency-driven headline growth.
6. Capital allocation cadence. With $1 billion in buybacks targeted by calendar year-end plus a fresh $2 billion authorization on top of the $382 million left from the 2024 program, watch for disclosed repurchase pace, debt paydown progress on the OneOncology-related term loans, and any dividend commentary (quarterly dividend was raised 9% to $0.60/share in November 2025).
7. Macro/policy backdrop: tariffs and MFN pricing. The industry is navigating a live policy overhang: a 100% ad valorem tariff on patented pharmaceutical products and their active pharmaceutical ingredients takes effect July 31, 2026 for large companies and September 29, 2026 for smaller manufacturers, while generics, biosimilars, and certain specialty products remain exempt for now, pending a formal review within one year. Separately, the administration has reached voluntary Most-Favored-Nation pricing agreements with 17 of the largest pharmaceutical manufacturers, which could layer onto the existing WAC-reduction dynamic that already pressured Cencora's U.S. revenue base this year. Management has consistently argued it can defend absolute gross-profit dollars even as WAC/MFN pricing pressures compress revenue — this thesis will likely be tested again in commentary and Q&A, especially since generics/biosimilars (COR's core distribution volume) remain tariff-exempt for now, which is a relative positive.
Cencora's fundamental story hasn't really changed since May: this is a company guiding to double-digit adjusted operating income and EPS growth even as headline revenue growth has been structurally reset lower by WAC/IRA pricing pressure, a large customer's channel shift, and slower GLP-1 growth — with margin resilience, OneOncology/RCA specialty scale, and buybacks doing the heavy lifting on EPS. The stock's near-full recovery from the May sell-off suggests the market has largely accepted management's framing that these are "transitory" or non-margin-dilutive issues. Tomorrow's print is less about a single beat/miss and more about whether (a) the promised second-half acceleration is visibly on track, (b) the mail-order/GLP-1 revenue headwinds are stabilizing rather than worsening, and (c) new CFO Eva Boratto reinforces continuity in the long-term algorithm (7-10% organic operating income growth, 10-14% EPS growth) that underpins the current valuation.